Tumor-agnostic CtDNA Levels by MFAST-SeqS in First-line HR-positive, HER2 Negative Metastatic Breast Cancer Patients As a Biomarker for Survival

Overview

Journal NPJ Breast Cancer

Date 2023 Jul 14

PMID 37452019

Authors

Noortje Verschoor

Vanja de Weerd

Mai N Van

Jaco Kraan

Marcel Smid

Joan B Heijns

Jan C Drooger

Johanna M Zuetenhorst

Annemieke van der Padt-Pruijsten

Agnes Jager

Stefan Sleijfer

John W M Martens

Saskia M Wilting

Affiliations

Soon will be listed here.

Abstract

This prospective cohort study reports aneuploidy score by mFast-SeqS as a strong prognostic marker in MBC patients. mFAST-SeqS is an affordable and easily implementable method for the assessment of total ctDNA levels and, as such, provides an alternative prognostic tool. One mixed cohort (cohort A, n = 45) starting any type of treatment in any line of therapy and one larger cohort (cohort B, n = 129) consisting of patients starting aromatase inhibitors (AI) as first-line therapy were used. mFAST-SeqS was performed using plasma of blood in which CTCs (CellSearch) were enumerated. The resulting aneuploidy score was correlated with categorized CTC count and associated with outcome. The aneuploidy score was significantly correlated with CTC count, but discordance was observed in 31.6% when applying cut-offs of 5. In both cohorts, aneuploidy score was a significant prognostic marker for both PFS and OS. In the Cox regression models, the HR for aneuploidy score for PFS was 2.52 (95% CI: 1.56-4.07), and the HR for OS was 2.37 (95% CI: 1.36-4.14). Results presented here warrant further investigations into the clinical utility of this marker in MBC patients.

Citing Articles

Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients.

Kirmizitas T, van den Berg C, Boers R, Helmijr J, Makrodimitris S, Dag H Genes (Basel). 2024; 15(6).

PMID: 38927686 PMC: 11203368. DOI: 10.3390/genes15060750.

References

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

Febbo P, Ladanyi M, Aldape K, De Marzo A, Hammond M, Hayes D . NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011; 9 Suppl 5:S1-32. DOI: 10.6004/jnccn.2011.0137. View

Bos M, Angus L, Nasserinejad K, Jager A, Jansen M, Martens J . Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis. Cancer Treat Rev. 2019; 83:101951. DOI: 10.1016/j.ctrv.2019.101951. View

Bakhoum S, Cantley L . The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment. Cell. 2018; 174(6):1347-1360. PMC: 6136429. DOI: 10.1016/j.cell.2018.08.027. View

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X . Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534(7605):47-54. PMC: 4910866. DOI: 10.1038/nature17676. View

Fadrosh D, Ma B, Gajer P, Sengamalay N, Ott S, Brotman R . An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome. 2014; 2(1):6. PMC: 3940169. DOI: 10.1186/2049-2618-2-6. View

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S . mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. Adv Exp Med Biol. 2016; 924:147-155. DOI: 10.1007/978-3-319-42044-8_28. View

Bidard F, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E . Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. JAMA Oncol. 2020; 7(1):34-41. PMC: 7645742. DOI: 10.1001/jamaoncol.2020.5660. View

Pierga J, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M . High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2011; 23(3):618-624. DOI: 10.1093/annonc/mdr263. View

10.

Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15(4):406-14. DOI: 10.1016/S1470-2045(14)70069-5. View

11.

Leary R, Sausen M, Kinde I, Papadopoulos N, Carpten J, Craig D . Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012; 4(162):162ra154. PMC: 3641759. DOI: 10.1126/scitranslmed.3004742. View

12.

Mendelaar P, Robbrecht D, Rijnders M, de Wit R, de Weerd V, Deger T . Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Mol Oncol. 2022; 16(10):2086-2097. PMC: 9120908. DOI: 10.1002/1878-0261.13196. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Suppan C, Brcic I, Tiran V, Mueller H, Posch F, Auer M . Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment. Cancers (Basel). 2019; 11(8). PMC: 6721524. DOI: 10.3390/cancers11081171. View

15.

Adalsteinsson V, Ha G, Freeman S, Choudhury A, Stover D, Parsons H . Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017; 8(1):1324. PMC: 5673918. DOI: 10.1038/s41467-017-00965-y. View

16.

Murtaza M, Dawson S, Tsui D, Gale D, Forshew T, Piskorz A . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. DOI: 10.1038/nature12065. View

17.

Angus L, Deger T, Jager A, Martens J, de Weerd V, van Heuvel I . Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. Clin Cancer Res. 2021; 27(10):2798-2806. DOI: 10.1158/1078-0432.CCR-20-3954. View

18.

Sauerbrei W, Taube S, McShane L, Cavenagh M, Altman D . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018; 110(8):803-811. PMC: 6093349. DOI: 10.1093/jnci/djy088. View

19.

Kruger D, Jansen M, Konings I, Dercksen W, Jager A, Oulad Hadj J . High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. Mol Oncol. 2019; 14(3):490-503. PMC: 7053245. DOI: 10.1002/1878-0261.12617. View

20.

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View